Overview

A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia

Status:
Not yet recruiting
Trial end date:
2026-02-26
Target enrollment:
Participant gender:
Summary
This study will be a single arm multicenter Phase II open-label, dose escalation study of asciminib in patients with CML-CP without T315I mutation who have had 1 prior TKIs for which they did not respond to treatment or were intolerant to treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals